Aquestive Therapeutics Inc (NASDAQ:AQST) saw an uptick in trading volume on Tuesday . 27,131 shares were traded during mid-day trading, a decline of 97% from the previous session’s volume of 897,614 shares.The stock last traded at $8.73 and had previously closed at $8.74.

A number of equities analysts recently weighed in on AQST shares. HC Wainwright reissued a “buy” rating and set a $14.00 price objective (up from $12.00) on shares of Aquestive Therapeutics in a report on Monday. Zacks Investment Research raised Aquestive Therapeutics from a “hold” rating to a “buy” rating and set a $6.00 target price for the company in a research note on Monday, November 11th. ValuEngine lowered Aquestive Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, Wedbush reiterated a “buy” rating and set a $37.00 price target on shares of Aquestive Therapeutics in a research report on Monday. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. Aquestive Therapeutics has an average rating of “Buy” and a consensus price target of $18.40.

The firm has a market capitalization of $195.09 million, a P/E ratio of -3.17 and a beta of 2.70. The firm’s 50 day simple moving average is $5.03 and its two-hundred day simple moving average is $4.17.

Large investors have recently made changes to their positions in the company. Meeder Asset Management Inc. lifted its stake in shares of Aquestive Therapeutics by 460.2% in the 3rd quarter. Meeder Asset Management Inc. now owns 8,129 shares of the company’s stock valued at $26,000 after acquiring an additional 6,678 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in shares of Aquestive Therapeutics in the third quarter worth $46,000. Morgan Stanley increased its position in shares of Aquestive Therapeutics by 706.1% in the second quarter. Morgan Stanley now owns 17,323 shares of the company’s stock valued at $73,000 after acquiring an additional 15,174 shares during the period. JPMorgan Chase & Co. increased its holdings in Aquestive Therapeutics by 728.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 22,761 shares of the company’s stock valued at $93,000 after purchasing an additional 20,014 shares during the period. Finally, Tower Research Capital LLC TRC purchased a new position in Aquestive Therapeutics during the 3rd quarter valued at about $94,000. 54.25% of the stock is currently owned by hedge funds and other institutional investors.

About Aquestive Therapeutics (NASDAQ:AQST)

Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally.

See Also: What is the float in trading stocks?

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.